Medicare Alzheimer's early detection

Full Title:
ASAP Act

Summary#

This bill would require Medicare to cover certain blood-based tests that screen for early or pre-symptomatic Alzheimer’s disease and related dementias. It defines which tests qualify and sets a start date of January 1, 2028. The stated policy goal is earlier detection of Alzheimer’s disease and related dementias.

  • Main change: Adds “Alzheimer’s disease and related dementias early detection screening tests” to the list of items Medicare will cover and pay for.
  • Covered tests: Tests must have FDA review (cleared, classified, or approved) and must be a genomic sequencing blood or blood-product test, or an equivalent test the Secretary of Health and Human Services allows (examples listed include single-analyte tests, cell-free nucleic acid analysis, multiplex panels, whole genome/exome/transcriptome, protein expression, and some imaging tied to biospecimens).
  • Timing: Coverage applies to tests furnished on or after January 1, 2028.
  • Secretary discretion: The Health Secretary can decide which other tests give results comparable to the named genomic blood tests.

What it means for you#

  • Medicare beneficiaries: Medicare recipients could have Medicare coverage (and payment) for certain blood-based tests that aim to detect Alzheimer’s disease before or in early stages. The bill does not state how often tests may be given, who is eligible, or how much beneficiaries would pay out of pocket.
  • Patients and families: This could make these tests easier to obtain for people on Medicare, but the bill does not describe follow-up steps, counseling, or treatment changes after a positive or uncertain result.
  • Doctors and clinicians: Clinicians could order FDA-cleared or approved blood-based screening tests for Medicare patients once the tests and policies are in place. The bill does not specify clinical guidelines, who should be screened, or when to screen.
  • Test developers and labs: Manufacturers of tests that have FDA clearance or approval and labs that perform those tests would become eligible for Medicare payment for covered tests. The Secretary can add other test types that give comparable results.
  • Medicare program and administrators: Medicare would need to add billing codes, payment rules, and coverage policies for these tests. The bill changes existing law so that payment is explicitly included.

Expenses#

No publicly available information.

  • The bill text does not include a fiscal note or cost estimate.
  • This could mean higher Medicare spending if many beneficiaries use the tests.
  • There could also be administrative costs for Medicare to set up coverage rules, payment codes, and oversight.
  • There may be additional downstream costs from follow-up testing, specialist visits, imaging, or treatments prompted by screening results. These follow-up costs are not specified in the bill.

Proponents' View#

  • The bill appears intended to expand access to early detection of Alzheimer’s disease and related dementias by making certain blood-based screening tests payable by Medicare.
  • Supporters may argue that covering validated blood tests will help find disease earlier, which could allow earlier care planning, monitoring, or treatment.
  • Making payment explicit can encourage test development and wider use of tests that have FDA review.

Opponents' View#

  • One concern is cost: the bill does not say how many tests Medicare will pay for or how often, so total program costs are uncertain.
  • The bill does not set clinical criteria for who should be screened, how often, or what follow-up care is required. This may lead to inconsistent use or unnecessary follow-up care.
  • The bill relies on FDA clearance/approval and the Secretary’s judgment about “equivalent” tests, but it does not define clinical performance standards (for example, sensitivity, specificity, or how to handle false positives/negatives).
  • It is unclear whether beneficiaries will face cost-sharing (co-payments) or whether screening will be part of preventive benefits with different cost rules.
  • The bill does not address counseling or support services for people who get positive or uncertain results, which could affect patient well‑being and the value of screening.